Join Naveris and change the future of HPV-driven cancer.
Our flagship product, NavDx, is a breakthrough blood-based test for HPV-associated cancer, clinically proven and already in use in the majority of centers of excellence treating HPV-associated oropharyngeal cancer (OPSCC) across the U.S. This first-to-market blood test is the only test available that supports HPV-cancer patients across the entire cancer journey: pretreatment, during treatment and in post-treatment surveillance.
